·       Except North India, the other three regions saw a decline in sales.

·       Launches declined in all the four regions with North India witnessing the maximum decline

New Delhi, November 27, 2025: Housing sales in India’s top 15 tier 2 cities fell 4% YoY to 39,201 units in Q3 2025 even as the sales value rose by 4% to Rs 37,409 crore indicating a gradual shift towards premium homes, according to a report by NSE-listed real estate data analytics firm PropEquity.

The new supply declined 10% YoY to 28,721 units in the third quarter ending September 2025.

Eight out of the fifteen cities saw YoY decline in sales with Bhubaneshwar witnessing the maximum decline at 26%. Trivandrum saw the maximum rise in sales at19% in Q3 2025.

Bhubaneshwar saw the maximum decline in new launches at 88% in Q3 2025. Eight out of fifteen cities saw a decline in new launches.

In volume terms, Ahmedabad remained the top market in terms of both sales and launches in Q3 2025.

Samir Jasuja, Founder and CEO, PropEquity said, “There has been a steady decline in new housing launches, especially in the high-volume affordable and mid-income segments. With rising input costs and evolving consumer aspirations pushing up home prices and home sizes, sales momentum in these markets has begun to moderate.”

“That said, Tier 2 cities remain the key engines of India’s growth story. Expanding employment opportunities, improving infrastructure, and stronger connectivity continue to drive sustained demand across residential, commercial, and retail real estate.”

On QoQ basis, housing sales fell by 3%, sales value by 1% and launches by 26% in Q3 2025.

Western India comprising Ahmedabad, Surat, Gandhi Nagar, Vadodara, Nashik, Nagpur and Goa saw 6% YoY and 4% QoQ decline in sales in Q3 2025. The western region accounted for 76% of the total sales.

Northern India comprising Lucknow, Mohali and Jaipur saw 16% YoY and 7% QoQ rise in sales in Q3 2025.

Southern India comprising Coimbatore, Trivandrum and Kochi saw 7% YoY decline and 3% QoQ rise in sales in Q3 2025.

Central and Eastern India comprising Bhopal and Bhubaneshwar saw 14% YoY and 13% QoQ decline in sales in Q3 2025.

Western India comprising Ahmedabad, Surat, Gandhi Nagar, Vadodara, Nashik, Nagpur and Goa saw 6% YoY and 18% QoQ decline in launches in Q3 2025. The western region accounted for 78% of the total launches.

The post Housing sales in India’s top 15 tier 2 cities fall 4% in Q3 2025; launches dip 10%: PropEquity appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

The Subject Expert Committee consists of domain knowledge experts from the fields of pulmonology, immunology, microbiology, pharmacology, paediatrics, internal medicine, etc.

M/s Serum Institute of India, Pune has presented a Recombinant Chimpanzee Adenovirus vector vaccine (Covishield) encoding the SARS-CoV-2 Spike (S) glycoprotein with technology transfer from AstraZeneca/Oxford University. The firm submitted safety, immunogenicity and efficacy data generated on 23,745 participants aged ≥ 18 years or older from overseas clinical studies. The overall vaccine efficacy was found to be 70.42%. Further, M/s Serum was granted permission to conduct Phase-II/III clinical trial on 1600 participants within the country. The firm also submitted the interim safety and immunogenicity data generated from this trial and the data was found comparable with the data from the overseas clinical studies. After detailed deliberations Subject Expert Committee has recommended for the grant of permission for restricted use in emergency situation subject to certain regulatory conditions. The clinical trial ongoing within the country by the firm will continue.

M/s Bharat Biotech has developed a Whole Virion Inactivated Corona Virus Vaccine (Covaxin) in collaboration with ICMR and NIV (Pune), from where they received the virus seed strains. This vaccine is developed on Vero cell platform, which has well established track record of safety and efficacy in the country & globally.

The firm has generated safety and immunogenicity data in various animal species such as mice, rats, rabbits, Syrian hamster, and also conducted challenge studies on non-human primates (Rhesus macaques) and hamsters. All these data has been shared by the firm with CDSCO. Phase I and Phase II clinical trials were conducted in approx.800 subjects and the results have demonstrated that the vaccine is safe and provides a robust immune response.  The Phase III efficacy trial was initiated in India in 25,800 volunteers and till date, ~22,500 participants have been vaccinated across the country and the vaccine has been found to be safe as per the data available till date.

The Subject Expert Committee (SEC) has reviewed the data on safety and immunogenicity of the vaccine and recommended for grant of permission for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains. The clinical trial ongoing within the country by the firm will continue.

M/s Cadila Healthcare Ltd., has developed a Novel Corona Virus-2019-nCov-Vaccine using DNA platform technology. The firm initiated Phase-I/II clinical trial in India in more than 1000 participants which is ongoing. The interim data suggests that the vaccine is safe and immunogenic with three doses when administered intradermally. Accordingly, firm has sought permission to conduct Phase-III clinical trial in 26000 Indian participants, which has been recommended by the Subject Expert Committee.

M/s Serum and M/s Bharat Biotech vaccines have to be administered in two doses. All the three vaccines have to be stored at 2-8° C.

After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for conduct of the Phase III .

The post Approval of COVID-19 virus vaccine appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

• To make India’s public health surveillance system more responsive and predictive to enhance preparedness for action at all levels.
• Citizen-friendly public health surveillance system will ensure individual privacy and confidentiality, enabled with a client feedback mechanism.
• Improved data-sharing mechanism between Centre and states for better disease detection, prevention, and control.
• India aims to provide regional and global leadership in managing events that constitute a public health emergency of international concern.

The white paper was released by NITI Aayog Vice Chairman Dr Rajiv Kumar; Member (Health) DrVinod K Paul; CEO Amitabh Kant; and Additional Secretary DrRakesh Sarwal.

‘Vision 2035: Public Health Surveillance in India’is a continuation of the work on health systems strengthening. It contributes by suggesting mainstreaming of surveillance by making individual electronic health records the basis for surveillance. Public health surveillance (PHS) is an important function that cuts across primary, secondary, and tertiary levels of care. Surveillance is ‘Information for Action’.

The Covid-19 pandemic has provided us with an opportunity to revisit (re) emerging diseases due to increased interaction between human-animal-environment. Early identification of this interference is essential to break the chain of transmissions and create a resilient surveillance system. This vision document is a step in that direction, it articulates the vision and highlights the building blocks. It envisions a citizen-friendly public health system, which will involve stakeholders at all levels, be it individual, community, health care facilities or laboratories, all while protecting the individual’s privacy and confidentiality.’

The white paper lays out India’s vision 2035 for public health surveillance through the integration of the three-tiered public health system into Ayushman Bharat. It also spells out the need for expanded referral networks and enhanced laboratory capacity. The building blocks for this vision are an interdependent federated system of governance between the Centre and states, a new data-sharing mechanism that involves the use of new analytics, health informatics, and data science including innovative ways of disseminating ‘information for action’.

The paper released today is envisagedto serve as a vision document to propel public health surveillance in Indiaand establish India as a global leader in the area.

The post Public Health Surveillance in India appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.